Crestchem Limited reported a net profit of ₹2.71 crore for the financial year ended March 31, 2026, compared to ₹2.73 crore in the previous year. The company's total income rose to ₹25.52 crore from ₹21.52 crore in FY25. The board has recommended a final dividend of ₹1.50 per share for the year.

The board of directors has approved the audited standalone and consolidated financial statements for the year ended March 31, 2026. The company's earnings per share (EPS) stood at ₹9.04 for FY26, down from ₹9.08 in the previous year.

Financial Performance

The company's financial performance for the year under review is summarized below:

*Each share having face value of ₹10/

Dividend Declaration

The board has recommended a final dividend of ₹1.50 (15%) per equity share of ₹10 each for the financial year ended March 31, 2026. The dividend is subject to the approval of shareholders at the ensuing annual general meeting.

Subsidiary and Expansion

During the year, the company incorporated Oleo Biosciences Private Limited as a wholly owned subsidiary with 75% shareholding. The subsidiary has been established to manufacture Medium Chain Triglyceride (MCT) Oil. Commercial production at the subsidiary is expected to commence during the fourth quarter of the financial year 2026-27.

The board believes that this project will diversify the company's business portfolio and strengthen its long-term growth prospects. The procurement and installation of plant and machinery for the project are currently in progress.

Crestchem Limited reported a net profit of ₹110.38 lakh for the quarter ended March 31, 2026, compared to ₹61.04 lakh in the corresponding period of the previous year. Revenue from operations for the quarter stood at ₹1,022.53 lakh, up from ₹723.20 lakh in Q4 FY25. For the full financial year FY26, the company recorded a net profit of ₹271.35 lakh on revenue of ₹2,960.74 lakh.

The Board of Directors, meeting on May 29, 2026, approved the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The board recommended a final dividend of ₹1.50 per equity share, or 15%, for the financial year 2025-26. This payout is subject to shareholder approval at the upcoming Annual General Meeting.

During the year, the company incorporated a subsidiary, Oleo Biosciences Private Limited, in Bangalore on March 31, 2026. Crestchem holds a 75% stake in the new entity. The subsidiary had not commenced commercial operations by the end of FY26, and no significant financial transactions were recorded other than subscription money receivables.

The board also approved the reappointment of key managerial personnel. Mr. Dipak Narendraprasad Patel, Mrs. Parul Dipak Patel, and Mrs. Tansi Nimit Patel were reappointed for five-year terms effective from October 1, 2026, and April 1, 2026, respectively. Furthermore, the board authorized an investment of up to ₹2.25 crore in the new subsidiary via loans or equity.

Financial Performance

The company's earnings per share (EPS) for the quarter ended March 31, 2026, increased to ₹3.67 from ₹2.03 in the same quarter of the previous year. Total income for the quarter rose to ₹1,042.91 lakh from ₹737.27 lakh. For the full year, EPS was recorded at ₹9.03, slightly lower than the ₹9.09 reported in FY25.

Standalone Financial Results (₹ in Lacs)

The statutory auditors, M/s. Samir M. Shah & Associates, issued an audit report with an unmodified opinion on the standalone and consolidated financial results.